← Back to Screener
Aldeyra Therapeutics, Inc. (ALDX)
Price$1.80
Favorite Metrics
Price vs S&P 500 (26W)-71.42%
Price vs S&P 500 (4W)23.05%
Market Capitalization$105.86M
All Metrics
Book Value / Share (Quarterly)$0.74
P/TBV (Annual)0.99x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.55
Price vs S&P 500 (YTD)-67.31%
EPS (TTM)$-0.56
10-Day Avg Trading Volume2.15M
EPS Excl Extra (TTM)$-0.56
EPS (Annual)$-0.56
ROI (Annual)-56.89%
Cash / Share (Quarterly)$1.16
ROA (Last FY)-46.97%
EBITD / Share (TTM)$-0.58
ROE (5Y Avg)-51.13%
Cash Flow / Share (Annual)$-0.55
P/B Ratio2.39x
P/B Ratio (Quarterly)7.04x
Net Income / Employee (Annual)$-4
Net Interest Coverage (TTM)-36.04x
ROA (TTM)-41.27%
EPS Incl Extra (Annual)$-0.56
Current Ratio (Annual)2.58x
Quick Ratio (Quarterly)2.56x
3-Month Avg Trading Volume2.48M
52-Week Price Return-13.68%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.08
52-Week High$6.17
EPS Excl Extra (Annual)$-0.56
Tangible BV CAGR (5Y)30.69%
26-Week Price Return-67.44%
Quick Ratio (Annual)2.56x
13-Week Price Return-55.69%
Total Debt / Equity (Annual)0.34x
Current Ratio (Quarterly)2.58x
Enterprise Value$51.07
Book Value / Share Growth (5Y)-13.74%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.16
3-Month Return Std Dev176.63%
Net Income / Employee (TTM)$-4
ROE (Last FY)-76.49%
Net Interest Coverage (Annual)-60.78x
EPS Basic Excl Extra (Annual)$-0.56
Total Debt / Equity (Quarterly)0.34x
EPS Incl Extra (TTM)$-0.56
ROI (TTM)-49.58%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.58
Forward P/E25.13x
Price vs S&P 500 (52W)-43.51%
Year-to-Date Return-64.67%
5-Day Price Return15.09%
EPS Normalized (Annual)$-0.56
ROA (5Y Avg)-36.93%
Month-to-Date Return8.28%
Cash Flow / Share (TTM)$-0.77
EBITD / Share (Annual)$-0.58
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-42.59%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.56
P/TBV (Quarterly)1.21x
P/B Ratio (Annual)7.04x
Book Value / Share (Annual)$0.74
Price vs S&P 500 (13W)-56.38%
Beta1.34x
Revenue / Share (TTM)$0.00
ROE (TTM)-63.75%
52-Week Low$1.07
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.33
4.33
4.33
4.25
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ALDXAldeyra Therapeutics, Inc. | — | — | — | — | $1.80 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Aldeyra Therapeutics is a clinical-stage biotechnology company developing medicines for immune-mediated and metabolic diseases. Its lead candidate, Reproxalap, is in late-stage development for dry eye disease and allergic conjunctivitis. The company's pipeline also includes candidates targeting retinal diseases, autoimmune conditions, and cancer.